title: Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib.
abstract: Contraception is recommended during imatinib therapy based on the teratogenicity data in rats. However, patients may become pregnant and here we describe a successful pregnancy and labor without any congenital anomaly in a patient with chronic myeloid leukemia (CML) under treatment with imatinib. The patient had received imatinib for 53 months before she became pregnant, with a complete cytogenetic response achieved after 6 months of therapy and a major molecular response (MMR) after 28 months. CML was in MMR at discovery of pregnancy and the fetus had been exposed to imatinib for 5 weeks. Treatment was discontinued, but MMR persisted during gestation.
authors.affiliation: Department of Internal Medicine, Fujita Health University, School of Medicine, Toyoake. mtsuzuki@fujita-hu.ac.jp
authors.forename: Motohiro
authors.initials: M
authors.lastname: Tsuzuki
authors.forename: Youko
authors.initials: Y
authors.lastname: Inaguma
authors.forename: Kousuke
authors.initials: K
authors.lastname: Handa
authors.forename: Akio
authors.initials: A
authors.lastname: Hasegawa
authors.forename: Yukiya
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Masato
authors.initials: M
authors.lastname: Watanabe
authors.forename: Syuichi
authors.initials: S
authors.lastname: Mizuta
authors.forename: Fumio
authors.initials: F
authors.lastname: Maruyama
authors.forename: Masataka
authors.initials: M
authors.lastname: Okamoto
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Emi
mesh_terms: D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007231:Infant, Newborn; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis / Q000188:drug therapy*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate